Kriya Therapeutics Acquires Redpin Therapeutics

Kriya Therapeutics Acquires Warden Bio

January 7, 2022

Biotechnology

Kriya Therapeutics acquired Warden Bio, obtaining exclusive rights to five preclinical AAV-mediated gene therapy programs targeting glycogen storage disorders and establishing a new Rare Disease Division. Warden Bio co‑founder Kunal Kishnani joins Kriya as President of the Rare Disease Division and Duke researchers associated with the programs will serve as scientific advisors.

Otsuka Pharmaceutical Acquires Jnana Therapeutics

August 1, 2024

Biotechnology

Otsuka Pharmaceutical Co., Ltd. will acquire clinical-stage biotech Jnana Therapeutics, making it a wholly owned subsidiary via Otsuka America, Inc. The deal values Jnana at $800 million in upfront cash plus up to $325 million in development and regulatory milestones and is intended to add Jnana's RAPID chemoproteomics platform and lead program JNT-517 (a potential oral PKU therapy) to Otsuka's specialty and autoimmune pipeline.

Intellia Therapeutics Acquires Rewrite Therapeutics

February 3, 2022

Biotechnology

Intellia Therapeutics has acquired Rewrite Therapeutics, a UC Berkeley–spawned startup developing DNA-writing genome editing technologies. The deal includes $45 million upfront and up to $155 million in research and regulatory milestones, expanding Intellia's in-house editing capabilities to potentially enable new precision editing strategies.

Harmony Biosciences Acquires Epygenix Therapeutics

April 30, 2024

Biotechnology

Harmony Biosciences has acquired Epygenix Therapeutics, adding a late-stage rare epilepsy franchise (including EPX-100 and EPX-200) to its CNS pipeline. Harmony paid $35 million in cash with up to $130 million in development/regulatory milestones and up to $515 million in potential sales milestones to complete the transaction.

Biogen Acquires Alcyone Therapeutics

September 19, 2025

Medical Devices

Biogen has acquired Alcyone Therapeutics to obtain the ThecaFlex DRx intrathecal drug‑delivery system, integrating Alcyone employees into Biogen’s product delivery solutions team. Alcyone will receive $85 million upfront plus contingent milestone payments; Biogen will handle development, commercialization and manufacturing of ThecaFlex DRx while Alcyone’s remaining therapeutic assets are being divested into Neela Therapeutics.

Roche Acquires Poseida Therapeutics

November 28, 2024

Biotechnology

Roche Holdings, Inc. has agreed to acquire San Diego-based Poseida Therapeutics for $9.00 per share in cash plus a contingent value right (CVR) for up to $4.00 per share, representing an aggregate equity value of up to $1.5 billion. The acquisition will bring Poseida's non-viral gene-editing platforms, allogeneic TSCM-rich CAR-T programs and in-house GMP cell therapy manufacturing into Roche's Pharmaceuticals Division to establish a new core capability in allogeneic cell therapy.